all report title image
  • Published On : Nov 2022
  • Code : CMI5355
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :

Sertraline hydrochloride is the hydrochloride salt of sertraline, a synthetic derivative of naphthalenamine with anti-serotoninergic and anti-depressant properties. Sertraline appears to selectively inhibit the neuronal uptake of serotonin, raising serotonin levels in the central nervous system. Sertraline hydrochloride tablets are used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder (SAD), and post-traumatic stress disorder.

The global sertraline HCl market is estimated to be valued at US$ 1,385.9 million in 2022 and is expected to exhibit a CAGR of 7.1% during the forecast period (2022-2030).

Figure 1. Global Sertraline HCl Market Share (%) in Terms of Value, By Application, 2022

Sertraline HCl  | Coherent Market Insights

Global Sertraline HCl Market: Drivers

Increase in the prevalence of mental disorders is expected to drive the global sertraline HCl market growth over the forecast period. For instance, according to data published by National Institute of Mental Health in January 2022, an estimated 21.0 million adults in the U.S. had at least one major depressive episode in 2020. This number represented 8.4% of all the U.S. adults in 2020.

Increasing product launches for sertraline HCl which is expected to drive the global sertraline HCl market growth during the forecast period. For instance, in November 2021, Camber Pharmaceuticals, a fully integrated international pharmaceutical company, announced that it had added sertraline hydrochloride tablets to their current portfolio, which is the generic version of Zoloft.  Zoloft is an antidepressant that belongs to a group of drugs called selective serotonin reuptake inhibitors (SSRIs), Zoloft is used to treat some types of depression, premenstrual dysphoric disorder (PMDD), social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), panic disorder (PD), and post traumatic stress disorder (PTSD).

CMI table icon

Sertraline HCl Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,385.9 Mn
Historical Data for: 2017-2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 7.1% 2030 Value Projection: US$ 2,407.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: 25 mg, 50 mg, 100 mg, Others
  • By Application: Obsessive-Compulsive Disorder, Depression, Panic Disorder, Premenstrual Dysphoric Disorder, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Accord Biopharma, Apotex Inc., Aurobindo Pharma USA, InvaGen, Lupin, Camber Pharmaceuticals, Mylan (a part of Viatris Inc.), Sun Pharmaceutical, Wockhardt, Alpic Biotech

Growth Drivers:
  • Increasing prevalence of mental disorder
  • Increasing product launches for sertraline HCI
Restraints & Challenges:
  • Product recall

Figure 2. Global Sertraline HCl Market Share (%), By Distribution Channel, 2022

Sertraline HCl  | Coherent Market Insights

Global Sertraline HCl Market– Impact of Coronavirus (COVID-19) Pandemic

The supply of raw materials required for the production of pharmaceuticals has been severely disrupted due to the forced quarantine and lack of labor during the COVID-19 pandemic. As the link between regional warehouses is not smooth, transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has negatively affected the supply chain of the global intraocular melanoma treatment market. Thus, COVID-19 pandemic is expected to have negative impact on supply chain of intraocular melanoma treatment market. According to an article published by the Exploratory Research in Clinical and Social Pharmacy journal in June 2021, a study was carried out to evaluate the impact of COVID-19 on pharmaceutical systems and supply chain in resource-limited countries in Sub-Saharan countries such as Namibia. This study revealed negative impact on availability and access of essential drugs, sanitation and hygiene products, and antimicrobials. Most pharmaceutical companies and pharmacies in Namibia experienced delayed manufacturing and distribution of drugs, which is attributed to reduced inter-country transportation of pharmaceutical goods and limited in-country capacity to manufacture drugs. For instance, according to a review article published by the European Pharmaceutical Review journal in November 2020, COVID-19 pandemic has caused major challenges with respect to drug shortages and increased manufacturing costs across the globe. Moreover, the same source stated that COVID-19 pandemic has also led to problems such as stockpiling drugs, transportation delay, and others. Some measures that can be taken to ease the supply of pharmaceuticals during the pandemic include next generation technologies such as digital network platforms designed to work across multiple pharmaceutical enterprises and ensure the timely delivery of drugs to patients across the globe.

Global Sertraline HCl Market: Restraint

The major factors that hinder growth of the global sertraline HCl market include product recall. For instance, in January 2018, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation, is recalling 30-count bottles of 25-mg Zoloft (sertraline hydrochloride) tablets, according to the January 10, 2018, U.S. Food and Drug Administration (FDA) Enforcement report. The company cited weight variations in the tablets that have caused superpotent and subpotent drugs.

Global Sertraline HCl Market: Key Players

Key players operating in the Sertraline HCl market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Accord Biopharma, Apotex Inc., Aurobindo Pharma USA, InvaGen, Lupin, Camber Pharmaceuticals, Mylan N.V. (a Part of Viatris Inc.), Sun Pharmaceutical, Wockhardt, Alpic Biotech

Sertraline HCl belongs to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). Sertraline HCl has the same mechanism of action as other SSRIs. It works by increasing the amount of serotonin that is available in the brain. Serotonin is a neurotransmitter, or chemical messenger, that is involved in regulating many elements of a person’s daily life, including mood, sleep, rewards, learning, and memory. Research has linked depression with low levels of serotonin. Sertraline increases the amount of serotonin present in the brain, helping to reduce chemical imbalances and improve a person’s overall mood. Sertraline is available as either an oral tablet or a liquid. Typically, a person takes a dose in the morning or evening, once a day. People using it to treat premenstrual dysphoric disorder may take it every day or only on select days of the month.

Market Dynamics

Key trends in the market include increasing prescription rate and expenditure for antidepressant drug which is expected to drive the market growth during the forecast period. For instance,  according to an article published in Springer Nature Switzerland AG in March 2021, stated that the total number of Ads (antidepressants) prescriptions dispensed during COVID-19 pandemic (January to December 2020) were 78 million, 4 million more than in 2019 that costed the National Health Service (NHS) is the publicly funded healthcare system in England, £139 million (US $170.7 million) more than in 2019. Sertraline, an SSRI antidepressant drug, alone accounted for an extra £113 million (US $ 138.7 million) during 2020 than in 2019.

 Key features of the study:

  • This report provides an in-depth analysis of the global sertraline HCl market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global sertraline HCl market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Accord Biopharma, Apotex Inc., Aurobindo Pharma USA, InvaGen, Lupin, Camber Pharmaceuticals, Mylan (a part of Viatris Inc.), Sun Pharmaceutical, Wockhardt, Alpic Biotech
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global sertraline HCl market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sertraline HCl market.

Detailed Segmentation:

  • Global Sertraline HCl Market, By Type:
    • 25 mg
    • 50 mg
    • 100 mg
    • Others
  • Global Sertraline HCl Market, By Application:
    • Obsessive-Compulsive Disorder
    • Depression
    • Panic Disorder
    • Premenstrual Dysphoric Disorder
    • Others
  • Global Sertraline HCl Market, By Distribution Channel  :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Sertraline HCl Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Teva Pharmaceutical Industries Ltd.,
    • Novartis AG
    • Accord Biopharma
    • Apotex Inc.,
    • Aurobindo Pharma USA
    • InvaGen
    • Lupin
    • Camber Pharmaceuticals
    • Mylan N.V. (a part of Viatris Inc.)
    • Sun Pharmaceutical
    • Wockhardt
    • Alpic Biotech

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global sertraline HCl market size is estimated to be valued at US$ 1,385.9 million in 2022 and is expected to exhibit a CAGR of 7.1% between 2022 and 2030
Factors such as increasing prevalence of mental disorders and increasing product launches for sertraline HCl which is expected to drive the market.
Depression segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include product recall
Major players operating in the market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Accord Biopharma, Apotex Inc., Aurobindo Pharma USA, InvaGen, Lupin, Camber Pharmaceuticals, Mylan (a part of Viatris Inc.), Sun Pharmaceutical, Wockhardt, Alpic Biotech

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo